Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.

about

Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modified, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction.

P2860

Q54945960-DE9F3995-FFE2-41D1-8E59-048B92FD3340 Q55715392-3BABA004-E0B7-4C9D-8062-4A6B2B9EEE37

P2860

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.

Item

http://www.wikidata.org/entity/Q41018640

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Spatiotemporal delivery of nan ...... n after myocardial infarction.

@en

type

Item

label

Spatiotemporal delivery of nan ...... n after myocardial infarction.

@en

prefLabel

Spatiotemporal delivery of nan ...... n after myocardial infarction.

@en

P1476

Spatiotemporal delivery of nan ...... n after myocardial infarction.

@en

P2093

Gaoxian Chen

http://www.w3.org/2001/XMLSchema#string

Haiqing Li

http://www.w3.org/2001/XMLSchema#string

Lei Lu

http://www.w3.org/2001/XMLSchema#string

Miao Lin

http://www.w3.org/2001/XMLSchema#string

Qiang Zhao

http://www.w3.org/2001/XMLSchema#string

Quan Qi

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Ye

http://www.w3.org/2001/XMLSchema#string

Zhengwen Ruan

http://www.w3.org/2001/XMLSchema#string

Zhize Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

Effects of intensive glucose lowering in type 2 diabetes

Angiomyogenesis for myocardial repair.

The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Development of multinuclear polymeric nanoparticles as robust protein nanocarriers.

Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Cardiovascular gene therapy: current status and therapeutic potential.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

P304

4835-4848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJN.S132064

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zeyu Xiao

P577

2017-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744119

http://www.w3.org/2001/XMLSchema#string

P932

5511023

http://www.w3.org/2001/XMLSchema#string

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.

about

P2860

P2860

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932